Dr. Sequist on Rationale for TATTON Trial in EGFR-Mutant Lung Cancer

TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancerПодробнее

TATTON: Updated results for patients with EGFR-mutant positive NSCLCПодробнее

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after pr...Подробнее

TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancerПодробнее

Dr. Wakelee on Rationale to Explore Osimertinib With Concurrent Chemotherapy in EGFR-Mutant NSCLCПодробнее

Sequencing of Therapies in EGFR-Mutant NSCLCПодробнее

Dr. Sequist on Frontline EGFR TKI Use in NSCLCПодробнее

TATTON trial – Savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC | Lecia SequistПодробнее

Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLCПодробнее

Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung CancerПодробнее

Dr. Sequist Discusses the Efficacy of CO-1686 for NSCLCПодробнее

Segment 1: EGFR TKIs in NSCLCПодробнее

IMpower150 Data for Immunotherapy Quadruplet in EGFR-Mutant Lung CancerПодробнее

Understanding EGFR Resistance in Patients With MET-Amplified NSCLCПодробнее

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLCПодробнее

Frontline Afatinib in EGFR-Mutant NSCLCПодробнее

Dr. Sequist Discusses the IMPRESS TrialПодробнее

Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6Подробнее

Dr. Wakelee on Benefits of Osimertinib in EGFR-Mutant NSCLC TreatmentПодробнее